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Finding a safe, effective and acceptable HIV prevention method is key to preventing new 
infections in women. Vaginal microbicide trials aim to do so, but adherence to study product 
remains a challenge in interpretation of study product effectiveness. Accurate and objective 
measures of adherence are critical in microbicide trials.  
Methods  
We compared two applicator tests, visual inspection of returned empty applicators (VIREA) and 
ultraviolet (UV) light assessment of empty applicators returned as used within a tenofovir 
(TFV) gel implementation trial. Sensitivity and specificity in a small pilot sample was assessed 
at two time points, approximately three months apart. Reliability and concordance of the 
techniques was also assessed. 
Results  
Sensitivity and specificity analysis of 24 sample applicators at time point 1 was 75.0% and 
66.7% for VIREA and 83.3% and 91.7% for UV light assessment, respectively; Sensitivity and 
specificity at time point 2 was 100% and 58.3% for VIREA and 100% and 66.7% for UV light 
assessment, respectively. Participants (n=115, median age 28 years) enrolled in the 
implementation trial at the Vulindlela Research Clinic, returned 1316 empty TFV applicators as 
used in January 2015. Assessment outcomes showed 78.8% agreement between VIREA and UV 
light techniques. Methods concurred that 22% of the returned empty applicators did not appear 
to be used. UV light assessment identified about 28% less product used, as compared to that 
returned as used by women. 
Conclusion 
UV light assessment appears to be a more accurate and less subjective measure of adherence as 
compared to VIREA. Further studies are needed to verify accuracy of UV light inspection 
against available DNA/protein biomarkers. UV light assessment can be used in combination 
with other biomarkers to identify potential challenges to adherence and inform targeted 
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The literature review describes key concepts surrounding adherence in microbicide trials, with a 
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CHAPTER 1: INTRODUCTION 
 
1.1 Background 
In 2012, the South African National HIV Prevalence, Incidence and Behavioural Survey estimated 
that 12.2% of the population (6.4 million persons) were HIV positive, an increase of 1.2 million more 
people living with HIV than the previous survey in 2008 (1). South Africa’s programme of increasing 
access to treatment has led to a decrease in AIDS related mortality and an increase in life expectancy. 
New infections, however, remain a particular concern, especially amongst female youth aged 15 - 24 
years where HIV incidence rates in 2012 were over four times higher than the HIV incidence rates in 
males of the same age group (2.5% vs. 0.6%) (1). Amongst the key behavioural determinants of HIV 
infection (low age at sexual debut, age-disparate relationships amongst young people, multiple sexual 
partnerships and inconsistent condom usage), women often find negotiating condom usage in their 
relationships a challenge. HIV prevention methods that can be utilised and controlled by women are 
key to our efforts in getting to zero new HIV infections in this vulnerable population in the developing 
world. Vaginal microbicide trials aim to develop a safe and effective microbicide product that is 
acceptable to women and that can be used by women without their partner’s knowledge (if need be) to 
prevent HIV acquisition. Experience has shown that the success of any prevention method under 
investigation in clinical trials depends not only on the actual efficacy of the product, but even more so 
on the study participant’s willingness and ability to use the product correctly and consistently as 
instructed (2, 3). Adherence, or rather the lack thereof, can adversely affect the outcome and 
interpretation of study product efficacy in clinical trials and can result in the abandoning of potentially 
effective HIV prevention methods (4).  
The Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 Tenofovir (TFV) 
Gel Efficacy trial not only showed that pericoital TFV gel reduced HIV acquisition by 39% overall, 
but that there was a 54% protective effect in those who were able to use two doses of gel for more 
than 80% of their sex acts (termed high adherers) (3). The hopes raised by this proof of concept trial 
were recently dashed by the overall outcome of the Follow-on African Consortium for Tenofovir 
Studies (FACTS) 001 study, which showed no effect of pericoital TFV gel in preventing HIV 
acquisition in women (5). Although the FACTS 001 trial’s overall analysis did not confirm the 
efficacy of TFV gel, a case-cohort substudy analysis showed that high levels of TFV detected in 
genital fluids was significantly associated with a 52% reduction in HIV acquisition (5, 6). However, 
while a protective effect was shown in women who used the TFV gel correctly and consistently, 
overall adherence in the FACTS 001 study was too low to show overall TFV efficacy. With FACTS 
001 unable to confirm the results of the CAPRISA 004 TFV Gel Efficacy trial, efforts to move TFV 
gel to licensure may be hindered.  
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Measurement of adherence to study product in microbicide trials is critical to validating study product 
efficacy (4, 7). Most microbicide trials rely on participant self-report of study product use (8). 
However, self-report relies largely on participant recall, and has been shown to overestimate actual 
product use when multiple measures of adherence were used (8, 9). In clinical trial settings, due 
consideration must be given to a real-time objective measure of vaginal microbicide study product 
adherence that will inform adherence support interventions during trial conduct, without 
compromising study blinding.  
In the CAPRISA 004 TFV gel efficacy trial, a new technique for assessing applicators, known as 
Visual Inspection of Returned Empty Applicators (VIREA) was introduced in an attempt to better 
quantify adherence to study product in the trial (10). The applicator test involved visually inspecting 
returned empty gel applicators for evidence of vaginal insertion according to set criteria. Although the 
applicator test was subjective, VIREA identified about 16% more applicators, amongst those returned 
as used and assessed, that had no visual evidence of vaginal insertion and may not have been 
vaginally inserted as compared to that reported by participants. The technique was also validated by 
linking VIREA assessments to detectable TFV levels in vaginal fluids at visits where vaginal 
specimens were taken from women in the TFV gel arm (10).  
Another applicator test, that has shown promise as a method of measuring adherence is inspection of 
returned empty applicators under ultraviolet (UV) light. The technique has been used primarily in 
assessing empty hydroxyethyl cellulose (HEC) placebo gel applicators, either in daily vaginal use or 
before-sex / after-sex application (11-14). The sensitivity and specificity of assessment by UV light 
has been shown to be comparable, and sometimes even better than other applicator tests like the dye-
stain assay (DSA) and visual inspection, with some authors suggesting UV light assessment be 
considered as an objective measure of product use in clinical trials (14). 
Little is known about UV light assessment of returned empty TFV gel applicators. In an attempt to 
find a more objective method of measuring adherence, this research project, as an ancillary project to 
the CAPRISA 008 TFV Gel Implementation trial, aimed to assess the accuracy of both VIREA and 
UV light assessments, as well as assess the reliability and concordance of the two methods of 
measurement. Women enrolled in the CAPRISA 008 TFV Gel Implementation trial used 1% TFV gel 
in a pericoital based regimen viz. BAT 24 (insert one gel up to 12 hours Before sex, one gel as soon as 
possible but within 12 hours After sex, and not more than Two gels in 24 hours), and were required to 
return empty (used) and unopened (unused) applicators at each visit to the pharmacy for reconciliation 
(15). A subset of empty applicators returned as used in the CAPRISA 008 TFV Gel Implementation 




1.2 Literature review 
1.2.1 Key Concepts  
1.2.1.1 Adherence in microbicide trials – need for an accurate and objective measure of product 
adherence  
There are two factors which determine the observed level of effectiveness of any candidate 
microbicide under investigation in clinical trials: the actual efficacy of the product, as well as the 
participant’s willingness and ability to use the product correctly and consistently as instructed (2, 3). 
Poor adherence and inability to accurately measure product adherence can compromise interpretation 
of microbicide trial results and can negatively impact the outcome of a clinical trial (4, 7).  
Studies have also shown that product effectiveness is often higher in women who achieve correct and 
consistent product use. In the CAPRISA 004 TFV Gel Efficacy trial adherence to study product was 
defined as “the estimated proportion of reported sex acts covered by two gel doses” (3). The study not 
only showed that TFV gel reduced HIV acquisition by an estimated 39% overall, but that there was a 
54% protective effect in those who were able to use two doses of gel for more than 80% of their sex 
acts (termed high adherers). The early termination, due to futility, of the daily 1% TFV gel and daily 
oral TFV arms in the Microbicide Trial Network (MTN) 003 / VOICE trial was in part attributed to 
low adherence. Adherence was estimated to be about 90% based on participant self-report and 86% 
based on counts of returned product (unused applicators and leftover pills). However, drug level 
analysis in a random sub-cohort revealed that TFV was only detected in about a quarter of samples, 
and more than half of the women had no TFV detected at any quarterly visit (16). The FACTS 001 
trial, in an effort to gather more information on the efficacy of 1% TFV gel used pericoitally (BAT 
24), was unable to corroborate the CAPRISA 004 TFV Gel Efficacy trial results, largely due to low 
overall adherence to study product (5, 6). FACTS 001 showed overall no effect of TFV gel in 
preventing HIV infection; however, analysis of a subset of participants in the TFV-treated group 
showed that TFV detected in the genital fluids of women who used the product consistently and 
covering more than 72% of their sex acts, conferred a protective effect with a 52% reduction in HIV 
acquisition. However, this subgroup represented only 20% of participants and was insufficient to 
confirm the efficacy of pericoital TFV gel in preventing HIV acquisition. The FACTS 001 study did, 
however, highlight the need for more research to understand the barriers to and motivators of product 
use (6). As can be seen, inadequate adherence poses a serious challenge to accurately estimating 
product efficacy.  
 
Many researchers agree that optimising adherence (17, 18), as well as objective and accurate 
measurements of adherence in future microbicide trials is a key challenge that needs to be addressed 
(3, 9, 18). Challenges to accurate measurement of product adherence can compromise interpretation 
of microbicide trial results (4, 9), highlighting the need for more respondent–independent behavioural 
5 
 
and biological measures for future microbicide trials (9, 18). The choice of the most appropriate 
adherence measurement tool depends on the usefulness and reliability of the method in light of the 
goal of the study: whether the researcher wants to understand, quantify, or influence adherence, as 
well as available resources (7, 9). The shift in microbicide research towards antiretroviral (ARV) 
based products has allowed for direct measurement of drug levels as a marker of product exposure, 
and an indicator of compliance. Measurement of drug levels in body tissues such as the vaginal tract 
or plasma, enables insight into the level of drug required to confer a protective effect, and is crucial in 
understanding trial results (17, 19). However, in an efficacy trial, to avoid unblinding, this is only 
possible at study completion, and cannot assess adherence in the placebo arm. In order to achieve the 
necessary drug levels at the site of infection, correct (as per product use instructions) and consistent 
(at every sexual encounter) use of study product during efficacy studies is essential. Rapid onsite 
assessment of product adherence during trial conduct will enable real-time identification of 
participants with adherence challenges, and allow for targeted adherence support interventions to meet 
the required adherence threshold.  
 
The focus of this research project is on two applicator tests, visual inspection and ultraviolet light 
assessment of returned empty applicators, as methods of measuring adherence in a microbicide trial 
that can also optimize adherence during trial conduct. 
 
1.2.2 Applicator tests as Measurement Methods 
1.2.2.1 VIREA in CAPRISA 004 
The primary adherence measure in the CAPRISA 004 TFV Gel Efficacy trial was applicator based – 
defined as the number of reported sex acts covered by two doses of gel (3). Other measures of 
adherence in this trial included a count of returned used applicators, as well as self-reported adherence 
to study product (20). In an attempt to improve measurement of adherence in the CAPRISA 004 TFV 
Gel Efficacy trial, an additional measure of adherence was introduced after month 15, whereby 
returned empty applicators were, in a standardised manner, subjectively assessed as “appears used” or 
“appears unused” by visual inspection for residue on the outside of the applicator as an indicator of 
vaginal insertion (10). The technique, coined VIREA, showed that 77.5% of the 59800 empty 
applicators returned as used and assessed using the stipulated assessment criteria appeared to have 
been vaginally inserted. The other 22.5% of empty applicators returned as used did not have any 
visual evidence of vaginal insertion (no visible residue, no mucous, gel, secretions, or hair on the 
applicator barrel nor any residue besides gel on the applicator tip) and may not have been inserted into 
the vagina. VIREA identified about 16% more applicators that may have not been vaginally inserted 
as compared to that reported by the study participants, leading the researchers to conclude that 
estimates of adherence based solely on counts of returned empty applicators without physical 
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inspection using the VIREA technique may very well be over-estimates. Linking VIREA assessments 
to detectable TFV concentrations in vaginal fluid at 375 study visits where vaginal specimens were 
collected in women assigned to the TFV gel arm, showed that TFV was four times more likely to be 
detected in vaginal fluid in women who had more than half their applicators assessed as “used” by 
VIREA as compared to those who had half or less than half assessed as “used”, thereby validating the 
process of VIREA. Even though the process of VIREA was standardised, the subjective nature of the 
technique remains a limitation (10).  
 
1.2.2.2 UV Light 
Visual inspection of applicators under 365 – 385nm UV light for evidence of vaginal insertion has 
been used as an adherence measurement method. Bodily fluids, including semen and cervicovaginal 
fluid (CVF), fluoresce under UV light. A streaked fluorescent pattern is considered to be a positive 
indicator of vaginal insertion (12). Moench et al. evaluated four microbicide gel adherence monitoring 
methods, namely 1) staining with Alcian Blue, 2) microscopic detection of vaginal cells after staining 
applicators with Iodine, and 3) direct inspection without staining under both ambient and 4) UV light. 
Results showed that UV light inspection of applicators had the highest mean sensitivity (84%) and 
specificity (83%) (12). The researchers found that the sensitivity of the method may be reduced to 
65% without prior gel application and may increase to 95% with prior gel insertion. This was 
attributed to the observation that both the accuracy of the methods and intensity of the signal 
increased after prior insertions, possibly because accumulated gel from prior doses in the vagina 
supported retention of mucous and cells being on the surface of the inserted applicator. Hence the 
authors expressed concern over the accuracy of the method in coitally based dosing strategies, and 
concluded that UV light inspection of polypropylene applicators should provide a quick, reliable and 
quantitative assessment of whether applicators have actually been vaginally inserted especially in 
daily dosing regimens. Moench’s research also showed that the mean reading time to read the full set 
of 250 applicators was only 15 minutes for UV light assessment (compared to a mean of 32 minutes 
under ambient light assessment). This rapid assessment rate was possible because the UV viewing box 
utilised by the researchers allowed for loading of 36 applicators onto a tray which was slid over rails 
into the viewing box allowing for multiple applicators to be viewed at a time (12). 
Further investigations into the fluorescent properties of 1% TFV gel and placebo gel, and an enhanced 
UV system with optimised UV light source were conducted for the FACTS 001 trial (personal 
correspondence, Sarah Cohen, Research Operations Manager: FACTS, 23 November, 2014). In 
comparing the fluorescent intensity of TFV gel, placebo gel and CVF as viewed under 360nm UV 
light, Moench found that although both TFV and placebo gel had modest fluorescent properties, CVF 
had approximately 20-fold greater fluorescent intensity, and neither gels caused detectable quenching 
of CVF fluorescence (21). Hence, there is little potential for unblinding if UV light assessment of 
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empty TFV gel and empty placebo gel applicators was used to assess adherence in a blinded, placebo-
controlled TFV vaginal microbicide gel study. In his initial publication using the original UV light 
system, Moench et al. expressed concern over the utility of UV light assessment of pre-sex applicators 
in coital-dosing strategies due to the reduced sensitivity of the method without prior-gel application 
(12). Subsequent evaluation of an enhanced UV system with optimised UV light source and filter 
which substantially improves illumination, allows for better detection of vaginally inserted applicators 
from “gel-naïve” participants (without prior gel dosing). Previous concerns about the accuracy of the 
method in pericoital dosing regimens, such as BAT24, appear to be overcome with this enhanced UV 
system (21).  
In comparing three approaches for assessing adherence to vaginal gel in clinical trials, namely two 
applicator tests (DSA and UV light Assessment), Wisebag, and self-reported adherence to a daily 
vaginal dosing schedule of HEC placebo gel, van der Straten et al. found that UV light assessment 
and DSA performed similarly with 95% sensitivity and 79% specificity of UV light assessment as 
compared to 97% and 79% with DSA. The study confirmed that compared to these applicator tests, 
self-report overestimated adherence; whereas Wisebag was found to underestimate adherence, likely 
due to the practice of “pocket dosing”, where more than one applicator is retrieved from the bag per 
opening event. The authors found UV light assessments to be faster than DSA (which required a 5-
hour dye-drying time), and enabled possible immediate adherence feedback to participants during 
study visits, and also concluded that DSA and UV light assessments should be considered objective 
measures of product use in future microbicide trials (14). 
Keller et al., in comparing DSA and UV light techniques to assess empty placebo applicators before 
and after sex, supported Moench’s findings in that the sensitivity of UV light assessment was higher 
for post-sex applicators than for pre-sex applicators (11).  
Thurman et al., in comparing visual and UV light inspection versus DNA/protein biomarkers of HEC 
placebo gel applicators found the sensitivity and specificity of both inspection methods to be higher in 
applicators inserted in the presence of vaginal gel (as in the post-coital dose of the BAT24 regimen) 
compared to those inserted in the absence of vaginal gel (as in pre-sex applicator) (13), even when 
using an optimised UV light source for UV light assessment. In assessing the inspection methods after 
30 days of storing the applicators, the study found a statistically significant increase in specificity of 
visual inspection assessments and a statistically significant increase in overall sensitivity of UV light 
assessment (13).   
1.2.2.3 Influence of training and experience on assessment outcomes 
The influence of factors such as assessor experience is discussed by Moench et al., who found that the 
accuracy of assessments by UV light or other methods was unaffected by the assessors’ prior 
laboratory experience (12). However, the study design did not allow for investigation into the effect of 
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assessor experience in the technique itself on assessment outcomes. Moench et al. believe that 
training by practical experience of reading a set of known inserted and non-inserted applicators allows 
assessors to establish assessment thresholds which are key to achieving accurate assessment outcomes 
(12). Thurman et al., by assessing applicators at two time intervals, found that assessor experience in 
the UV light assessment technique did influence the assessment outcomes, with improvements in both 
sensitivity and specificity at 30-day readings as compared to 7-day readings. The study noted 
significant variability between assessors in several of the UV light assessments, concluding that UV 
light assessment remains subjective (13). However, there is insufficient information on training in the 
methodology section of this publication to elaborate further. 
A summary of the literature reviewed for the purpose of this dissertation is presented in appendix A.  
 
1.3 Problem Statement 
Objective methods of measuring adherence in clinical trials, although critical to assessing the 
effectiveness of the candidate microbicide under investigation, are lacking. Ideally, these should be 
reliable, inexpensive to implement, be able to be performed in real-time to inform adherence support 
interventions and without the risk of compromising study blinding. 
Research of UV light assessments of returned applicators has primarily been done with HEC placebo 
gel applicators under strict study conditions, either where the majority of applicators were inserted 
under direct observation, and only a subset were inserted at home (12); or where the dosing regimen 
was daily dosing (14). Sensitivity and specificity of UV light assessment of empty TFV gel 
applicators has not yet been established.  
UV light assessment of returned empty TFV gel applicators from an implementation study using a 
pericoital dosing strategy (BAT24), has, to the best of my knowledge, not yet been studied. 
 
1.4 Research Question  
Is assessment of returned empty TFV gel applicators by UV light comparable (in terms of accuracy, 
reliability and practicality) to assessment of the same applicators by VIREA? Is UV light assessment 
of returned empty TFV gel applicators less subjective than VIREA? 
1.5 Aim and objectives 
1.5.1 Aim  
The aim of this research proposal is to assess the accuracy, reliability and practicality of UV light 
assessment of used TFV gel applicators as compared to assessment by VIREA as an adherence 




Objective One: To undertake a pilot study to estimate the accuracy of both VIREA and UV light 
assessments of empty TFV gel applicators by calculating the sensitivity and specificity of the 
techniques, within four months of applicator receipt. 
Objective two: To assess the effect of storage on the sensitivity and specificity of the two techniques 
after an additional three months of storage. 
Objective Three: To assess the reliability and concordance of UV light assessment of a subset of 
returned used / empty TFV gel applicators in a select one-month period for agreement, with the 
VIREA assessment of the same applicators, in terms of evidence of vaginal insertion. 
Objective Four: To measure the time taken to assess a set of returned used / empty applicators for 
each technique in order to evaluate the practicality and efficiency of the measurement methods. 
 
1.6 Conceptual Framework 
Methods to measure adherence in microbicide trials can be classified into 3 broad categories (figure 
1), viz. 1) behavioural, 2) biologic or surrogate markers and 3) biomarkers (9). Each method measures 
a different dimension of adherence; and the triangulation approach to adherence measurement 
employs methods with complementary strengths, to enable a researcher to capture the most relevant 
adherence information for a given candidate microbicide product. 
Figure 1. Methods of measuring adherence in microbicide trials       
           
1.6.1 Behavioural measurement methods  
1. Participant self-report of adherence to product, whether prospectively (e.g. paper diaries) or 
retrospectively (e.g. face to face interviews) is prone to error, both unintentionally (recall bias) 
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and intentionally (social desirability bias) (9, 18). Errors may also occur on the part of staff 
documenting the participant’s response (recording bias), and also if confusion exists in what is 
actually being measured (instruction bias). Self-report, by any means, is relatively low-cost, 
versatile and simple to implement. However, self-report of adherence in microbicide and oral 
pre-exposure prophylaxis (PrEP) studies, has been shown to be upwardly biased (8, 9) i.e. self- 
report, as a measure of adherence, often overestimates adherence or product usage. 
 
2. Clinic counts of returned product (returned empty and unused applicators) enables full 
applicator accountability, and since it does not rely on participant self-report has been 
considered an easy “objective” measure of adherence; but this method is still open to bias in 
accuracy of counts, and is dependent on the participant returning empty and unused applicators 
at every visit. Counting of returned empty applicators as proxies for use may overestimate 
adherence (18), since simple tallies of empty applicators as used cannot account for gel 
expelled ex-vivo without vaginal insertion. 
 
3. Electronic dose monitoring (EDM) is by means of an electronic device that monitors container 
openings as a proxy for product use and adherence (e.g. EDM-adapted Wisebag, a lunch-bag 
style container – for storage of applicators – fitted with a battery-operated electronic device 
and chip that transmits an electronic signal for each opening event). In studies assessing this 
technology, participants are usually given instructions to open the unit only to retrieve an 
applicator for use (or in some cases return a used applicator for storage), so that each opening 
event theoretically provides data on applicator use in real time (14). EDM of gel usage may 
well overcome some of the limitations of participant self-report, providing detailed 
information on date / time of product retrieval, but cannot truly measure actual product use 
(whether the applicator was merely taken out of the bag or actually inserted, or even if gel was 
expelled vaginally) (9). EDM is limited primarily by expense in large scale trials; may present 
other challenges to participants in terms of acceptability (bulkiness, impracticality, and low 
portability); and may also underestimate adherence due to “pocket dosing” or overestimate 
adherence in “curiosity events” (with additional unintentional opening of the Wisebag for 
reasons other than retrieval of gel) (22). A potential benefit of the Wisebag is that it may be set 
up to send a Short Message Service (SMS) reminder to a user either when no opening event is 
detected, or perhaps even when more opening events are detected than expected, to alert the 
user to possible overuse of study product (9, 22, 23). The latter is especially useful where there 




1.6.2 Biologic / surrogate markers 
1. Dye-stain assay (DSA) involves staining of returned used applicators with a food dye, such as 
FD&C Blue dye No.1, in order to assess whether the applicators were actually vaginally 
inserted by visually detecting the dye-stained vaginal mucous. The test is relatively easy to 
implement, and has been validated with different gels, applicator types and dosing strategies. 
Although DSA appears to perform well with polyethylene applicators, sensitivity of the 
technique with multiple gel applications was significantly lower for polypropylene 
applicators, such that authors do not recommend DSA for polypropylene applicators that are 
currently used in microbicide trials (24). The time taken for the dye to dry after staining and 
prior to visual inspection, together with safety and toxicity concerns of certain dyes (e.g. 
trypan blue) limit utility of this technique (9). 
 
2. UV light assessment technique is based on the practice of using UV light in forensic detection 
of bodily fluids, and in microbicide trials involves inspecting returned empty applicators 
under UV light at 365-385nm for signs of vaginal insertion. Semen and CVF fluoresce under 
UV light and so too may microbicide gels, and the test is unable to differentiate between 
them. It is therefore pertinent to understand the fluorescent properties of microbicide gels 
under investigation, and their effect on the fluorescent signal intensity of CVF if this 
technique is to be considered for use in future microbicide gel trials. Gel dosing regimen may 
affect the test sensitivity of UV light inspection of returned empty applicators. Reduced 
sensitivity without prior gel dosing or pre-sex application has been shown in several studies: 
Moench et al. reported sensitivity of 65% without prior gel application (as may occur in coital 
based regimens), and 95% with prior gel application (as in daily dosing regimens) (12); Keller 
et al. reported 87% sensitivity for pre-sex applicators and 97% for post-sex applicators (11). 
The UV light viewing box is relatively small and portable. With training, the technique can 
provide an accurate assessment of vaginal insertion, and has been shown to have the highest 
accuracy in correctly identifying the insertion status of an applicator as compared to other 
applicator tests (12). 
 
3. Ambient light assessment involves visual inspection, according to predefined criteria, of 
returned empty applicators under ambient light for residue (secretions and/or gel) that may be 
indicative of vaginal insertion. The technique is cheap, requiring little to no ancillary 
equipment, and is easy to implement as an adherence measurement technique (10). This 
technique also allows for real-time feedback to guide targeted adherence interventions 
especially with regards to the mechanics of gel insertion (e.g. rapid identification of used 
applicators with incomplete / partially expelled gel). The technique has been shown to have a 
statistically significant lower specificity as compared to UV light assessment and staining 
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with Alcian Blue or Iodine (12). The specificity of the technique has also been shown to 
significantly increase after storage of applicators for 30 days as compared to assessment at 7 
days (13).  
 
Applicator tests, such as DSA, ambient and UV light assessments, all have inherent limitations. 
The following are to be noted: a) applicator tests cannot definitively assess actual product use 
(timing of use in relation to sexual activity or HIV exposure, or the amount of product used); b) 
applicator tests are unable to differentiate between an applicator vaginally inserted with gel 
expelled outside the vagina, or those truly inserted vaginally with gel expelled vaginally as per 
instructions for use (9); and, c) applicator tests may not be able to correctly identify applicators 
that have been used and wiped or washed after use, as may be a common practice in the field for 
reasons of discretion, as used.  
1.6.3 Biomarkers  
The use of ARV-based study products allow for study drug levels to be quantitatively measured in 
plasma, genital and rectal compartments; and these biomarkers may be crucial to help in interpretation 
of trial results. However, they have several limitations in that they can only be used in the active arm 
and, due to the potential to unblind, can only be used retrospectively in blinded studies, and hence are 
less useful to guide targeted adherence interventions (9). They also may be of limited value in 
intermittent pericoital dosing regimens (since a drug may only be detected for a limited time after last 
use, and the interval between last use and sampling may be variable) (9). Greater access to PrEP, such 
as Truvada for HIV prevention, and possible inclusion as standard of care in microbicide trials, may 
limit the utility of measured drug levels as a marker of adherence (25). In addition, cost may prove 
prohibitive.  
 
The choice of the most appropriate adherence measurement tool in microbicide trials is guided by the 
candidate microbicide and product formulation; the utility and reliability of the method considering 
the goal of the study; what the researcher aims to achieve in term of adherence measurement; and 























CHAPTER 2: METHODOLOGY 
 
2.1 Study Setting and considerations 
This research project was undertaken as a substudy within the CAPRISA 008 TFV Gel 
Implementation trial, an open-label randomized controlled trial to assess the implementation 
effectiveness and safety of 1% TFV gel provision through family planning (FP) services in KwaZulu-
Natal, South Africa, which provided post-trial access of TFV vaginal gel to HIV-uninfected women 
who previously participated in the CAPRISA 004 TFV Gel Efficacy trial (15). Eligible women were 
randomly assigned to receive their TFV gel either through FP services coinciding with their 
contraceptive schedule (intervention arm), or monthly though the CAPRISA research clinics (control 
arm). They were required to return all unused and used/empty applicators to pharmacy for 
reconciliation at each study visit – either every two or three months in the intervention arm or monthly 
in the control arm. Determination of adherence to study product or regimen in CAPRISA 008 TFV Gel 
Implementation trial was three-fold: brief interviewer-administered questions at each study visit, counts 
of returned used and unused applicators at each study visit, and post-trial analysis of TFV 
concentrations in genital specimens collected at four bi-annual visits and study exit will aid in 
assessing product adherence and interpretation and understanding of trial results (15).  
For the purpose of this research project, a subset of empty applicators returned as used by women 
enrolled in the CAPRISA 008 TFV Gel Implementation trial at the CAPRISA Vulindlela Clinic were 
assessed.  
The aim of this research proposal is to assess the accuracy, reliability and practicality of UV light and 
VIREA assessment techniques. The accuracy of a test procedure is best measured in terms of 
sensitivity (the ability of a test to accurately identify a condition when present) and specificity (the 
ability of a test to accurately identify those in whom the condition is absent). Reliability is defined in 
the Merriam-Webster dictionary as “the extent to which an experiment, test, or measuring procedure 
yields the same results on repeated trials”. In terms of this research proposal, reliability of the 
assessment criteria for each assessment technique will be assessed by comparing the inter-assessor 
agreement, and furthermore, by assessing concordance of assessment outcomes by each technique. 
Practicality of the methods will be assessed in terms of efficiency (time-taken to complete 





2.2 Data Collection 
2.2.1 Training 
Prior to conducting any assessments, two pharmacists underwent training on the techniques of VIREA 
and UV light inspection. The CAPRISA 004 Vulindlela site VIREA assessor, with prior experience in 
the VIREA assessment technique developed and utilised in CAPRISA 004 TFV Gel Efficacy trial, 
conducted a training and practical demonstration session of the VIREA technique for the new VIREA 
assessors. The CAPRISA 004 Vulindlela site VIREA assessor then set up a competency test for the 
new VIREA assessors with a selection of applicators returned as used.  
Training in the technique of UV light assessment was conducted by the Masters student through 
images (figure 3) shared by Sarah Cohen, the Research Operations Manager for FACTS, WITS 
Reproductive Health & HIV Institute, as well as practical viewing of applicators returned as used. A 
competency test consisting of known to be vaginally inserted applicators and sham-inserted 
applicators (gel expelled ex-vivo, applicator handled but not vaginally inserted) was conducted.  
Pharmacy staff had to pass both these independently conducted competency tests with 100% to 
qualify as an assessor (appendix B and C).  
2.2.2 Sample for assessing sensitivity and specificity 
Since there is limited sensitivity or specificity data on the use of VIREA and UV light assessments of 
empty TFV gel polypropylene applicators, this project aimed to estimate sensitivity and specificity as 
a pilot in a limited sample. Sample size as calculated using NQUERY advisor, Version 7.0: assuming 
the sensitivity of UV light will be between 73% and 95% then a sample of 12 used and 12 unused 
applicators will lead to a 95% 2-sided confidence interval that will extend 0.251 from the observed 
proportion if the observed proportion is 0.73 and 0.123 if the observed proportion is 0.95.   
Assuming the specificity of UV light to be between 66% and 95% then a sample of 12 used and 12 
unused applicators will lead to a 95% 2-sided confidence interval that will extend 0.268 from the 
observed proportion if the observed proportion is 0.66 and 0.251 if the observed proportion is 0.95. 
The known to be vaginally inserted applicators (positive controls) for this pilot assessment were 
provided by volunteers within the CAPRISA 008 TFV Gel Implementation trial. The volunteers came 
to the clinic to insert either their before sex or after sex gel dose under direct observation. Sampling 
methodology was purely convenience sampling. Negative controls comprised of “sham-inserted” 
applicators - TFV gel applicators which had been handled, with gel expelled ex-vivo, but not inserted 
vaginally.  
To further assess the effect of storage on the sensitivity and specificity of the techniques, the same set 
of applicators, after assessment by VIREA and UV light at time point one, were then retained and 
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stored at controlled room temperature for subsequent assessment at time point two after an additional 
three months of storage.  
2.2.3 Sample for assessing concordance of techniques 
A sample of approximately 1000 applicators (based on the median monthly number of applicators 
returned as used in the CAPRISA 008 TFV Gel Implementation trial of 1008 (IQR 841 – 1172)) is 
adequate to assess the reliability and concordance of the methods of measurement under examination. 
Hence, a convenience sample of all empty CAPRISA 008 study gel returned by study participants as 
“used” during January 2015, were first subjected to assessment by VIREA, and subsequently and 
independently by UV light inspection, by two assessors in a standardised manner. Assessments were 
performed by both assessors independently to verify the reliability of the assessment criteria. 
However, for the purpose of assessing concordance of the techniques, only the assessment outcomes 
of the primary assessor were taken into consideration. 
2.2.4 Assessment procedures 
Assessors were blinded to the positive and negative controls, where used. Applicators were assessed 
according to standardised criteria for each method independently, so that assessment outcomes for one 
technique did not influence the other. Prior to assessment, every returned applicator was identified by 
a consecutive number on the outside of its resealable plastic packaging. VIREA inspection preceded 
UV light assessments, and every effort was made to minimise contamination of the returned empty 
applicators between these assessments. This included the use of gloves to handle the returned empty 
applicators, only handling the applicators by the ridged end of the applicator barrel, and carefully 
returning each applicator to its numbered resealable plastic bag after assessment. 
The outcomes of assessments of returned empty applicators by the processes of VIREA and UV light 
assessment were documented on the logs developed for this purpose. The log for sensitivity and 
specificity analysis (appendix D and E) document the date of assessment, time taken for assessment, 
initials of assessor and assessment outcome. The log for assessment of concordance of the techniques 
(appendix F and G) records the participant unique identifier (PID), the visit code and date the study 
product was issued / dispensed, the date and quantity of empty applicators returned by the participant, 
the date assessed by VIREA or UV light and the initials of the assessor, and the assessment outcome.  
To compare the efficiency of each technique, the time taken to process a set of returned empty 
applicators by each technique was also documented.  This together with the assessors’ perspective on 
feasibility of incorporating the technique into workflow procedures, will enable evaluation of the 
practicality of each technique. 
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2.2.4.1 VIREA Assessments  
The following VIREA assessment guidelines, as utilised in CAPRISA 004 TFV Gel Efficacy trial, 
used to assess the appearance of the returned ‘used’ applicators, were applied: 
1. Each used applicator is individually removed from its resealable plastic bag packaging. 
2. The applicator barrel is inspected for any visible residue, mucus, gel, secretions or hair (figure 
2). If any substance is visible on the barrel, besides the tip where the gel is expelled, then the 
applicator should be categorised as used. 
3. If in step 2, the applicator barrel appears to have no residue of any kind, then the tip should be 
inspected.  If the applicator is capped, then the cap should be removed and the tip of the 
applicator should be inspected. If the tip is discoloured or has residue that is not gel, then the 
applicator is regarded as used. 
4. If in step 2 the barrel is clean and in step 3, the tip is clean or has a small point of gel as one 
would find if the gel was squirted out or if a small amount of ‘clean gel is visible’ then the 
applicator is regarded as unused. 
The outcomes of assessments of returned empty applicators by the processes of VIREA were 




              
             
Figure 2. Applicators with visible residue, mucus, gel, secretions or hair are assessed by VIREA 
as “used” (Pictures courtesy of Dr Leila E Mansoor, CAPRISA) 
 
2.2.4.2 UV Light Assessments  
A viewing box, based on that proposed by Moench et al. (12) was utilised to view the returned empty 
applicators under UV illumination (appendix H). UV light was provided by a UVL-21 Compact UV 
Lamp (365-nm). Applicators were viewed through a 76- x 102-mm Tiffen UV Haze-2A filter to block 
transmission of reflected source illumination.  
The following guidelines in assessing the appearance of the returned ‘used’ applicators by means of 
UV light inspection were applied: 
1. Push test applicator through the applicator porthole.  
2. Turn on the UV light and view the applicators through the viewing window.  
3. Score according to the following criteria: 
 “Appears used” – a streaked pattern of blue-green fluorescence on the barrel of the applicator 
(figure 3a, 3b) 
“Appears possibly used” – a generalised fluorescence with or without fluorescent speckles (an 
indication of possible usage / insertion of gel e.g. applicator may have, for reasons of 
discretion, been wiped post insertion and prior to returning to the clinic) (figure 3c, 3d) 
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“Appears unused” – absence of streaked or generalised fluorescence, with or without 
fluorescent speckles especially if these are limited to the area around the cap (figure 3e, 3f) 
The outcomes of assessments of returned empty applicators by UV light assessment were documented 




Figure 3a      Figure 3b 
Figure 3c     Figure 3d 
 
Figure 3e     Figure 3f 
 
Figure 3. Applicators as viewed under 365nm UV light. Figure 3a and b are assessed by UV 
light as “appears used”; Figure 3c and d are assessed by UV light as “appears possibly used”; 
Figure 3e and f are assessed by UV light as “appears unused”.  
(Pictures 3a, b, e and f courtesy of Dr Sarah Cohen, Wits Reproductive Health and HIV Institute; 




2.3 Data Analysis 
The sensitivity (proportion of applicators known to have been inserted vaginally which are correctly 
identified as such) of VIREA and UV light techniques were estimated using the positive controls. The 
specificity (proportion of applicators known to have not been inserted vaginally which are correctly 
identified as such) of the two techniques were estimated using “sham-inserted” applicators. 
The sensitivity and specificity, as well as the 95% confidence intervals, were calculated using the 
standard formulas: 
Sensitivity (%) = 100 x true positive / (true positive + false negative), 
Specificity (%) = 100 x true negative / (true negative + false positive).  
For the purpose of assessing reliability and concordance of the techniques, data captured on the 
assessment logs (appendix F and G) was subjected to a quality control process prior to capturing in an 
Excel database, and then imported to IBM SPSS Statistics Version 23 for further analysis. Percent 
agreement and the Kappa statistic was performed to assess interrater (inter-assessor) reliability, as 
well as reliability of the assessment techniques. 
Average times taken to assess 100 empty applicators by each technique were calculated to assess 
efficiency of the techniques.  
2.4 Ethical Considerations 
Prior to commencement of this research project, ethical approval was obtained from the University of 
KwaZulu-Natal’s Biomedical Research Ethics Committee (BREC), reference number BE083/15 
(appendix I). 
The assessment, and outcome of assessment, of empty TFV gel applicators returned by participants in 
the CAPRISA 008 TFV Gel Implementation trial, in no way affected their participation in the study or 
post-trial access to study product. Since study participants enrolled in the CAPRISA 008 TFV Gel 
Implementation trial were required to return both their used / empty and unused study product at 
every visit, this research project placed no additional burden on them.  
The only participant identifiers utilised in this research project were the participant unique identifier 
(PID), a number which links the participant unique number (last 4 digits) to study and site; there is no 
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Accurate and objective measurement of adherence is critical in microbicide trials. We compared 2 
applicator tests: visual inspection of returned empty applicators (VIREA) and ultraviolet light (UVL) 
assessment in terms of sensitivity and specificity, and for concordance. Sensitivity and specificity 
analysis of 24 control applicators at 4-months after receipt was 75.0% and 66.7% for VIREA and 
83.3% and 91.7% for UVL, respectively. After an additional 3 months of storage sensitivity and 
specificity was 100% and 58.3% for VIREA and 100% and 66.7% for UVL, respectively. In January 
2015, 1316 empty applicators were returned as used by 115 participants enrolled at one site in a 
randomized controlled trial. Assessment outcomes showed 78.8% agreement between the 
techniques. Methods concurred that 22% of the returned empty applicators did not appear to be used. 
By UVL assessment, 40% of returned empty applicators had no evidence of vaginal insertion, 
translating to 28% less product used as compared to that returned as used by women. UVL 
assessment may be considered a more accurate and less subjective measure of adherence as 





Finding an effective and acceptable HIV prevention method that can be controlled by women is key in 
efforts to getting to zero new HIV infections in this vulnerable population in the developing world, 
where negotiating condom use is oftentimes challenging. Research has shown that the effectiveness 
of any prevention method under investigation in clinical trials depends not only on the true efficacy of 
the product, but more importantly on the participant’s willingness and ability to use the product both 
correctly and consistently as instructed (1, 2). Adherence, or rather the lack thereof, can adversely 
affect the outcome of clinical trials and can result in the abandoning of potentially efficacious 
prevention methods (3).  
 
The Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 phase IIb trial to 
assess the safety and effectiveness of the vaginal microbicide 1% tenofovir (TFV) gel for the 
prevention of HIV infection in women in South Africa, not only showed that pericoital TFV gel reduced 
HIV acquisition by 39% overall, but that higher gel adherence (using two doses of gel for more than 
80% of sex acts) conferred a greater protective effect, reducing HIV acquisition by 54% (2). However, 
disappointingly low adherence to TFV gel in two other recent studies contributed to a failure to 
demonstrate a protective effect of TFV gel (4, 5), potentially hindering the path to licensure of TFV gel 
as an HIV prevention method. 
 
Added to the deleterious effect of low adherence on clinical trial outcomes, challenges in accurately 
measuring adherence can also adversely compromise the interpretation of trial results (6). As such, 
measurement of adherence to study product is critical for validating study product efficacy (3, 7). 
Finding the most appropriate adherence measure, or combination of measures, is an essential 
consideration in trial design. The choice of the most appropriate adherence measure depends on the 
usefulness and reliability of the method in light of the goal of the study, and available resources (6, 7).  
 
The shift in the microbicide development pathway towards antiretroviral based products allows for 
measured drug levels to be used as markers of exposure. Directly measuring drug levels in body 
tissues is crucial in interpretation of trial results, however utility is limited by cost and invasiveness, as 
well as timing in relation to study product use in pericoital dosing, and retrospective use in placebo 
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controlled trials (6). A real-time objective measure of microbicide product adherence that will not 
compromise study blinding, but that will inform adherence support interventions during trial conduct, is 
an important consideration especially in a blinded clinical trial assessing effectiveness of a candidate 
microbicide product. 
 
Most microbicide trials rely on participant self-report of study product use (8). Self-reported 
adherence, although relatively low cost and simple to implement (6), may be subject to recall and 
social desirability bias (9), and has been shown to overestimate actual product use when multiple 
measures of adherence were used (8). Other more costly measures like electronic drug / dose 
monitoring (EDM) may not accurately measure actual product use (6), and EDM-adapted 
technologies such as the Wisebag™ may underestimate product usage as it is unable to monitor the 
practice of “pocket-dosing” where more than one applicator is retrieved per bag opening, or may 
overestimate product usage with curiosity openings of the bag (10, 11). Directly observed insertion 
(DOI), used in intravaginal microbicide ring trials at clinic visits is best suited for controlled drug 
release dosage forms, but does not monitor participant-initiated ring removals (6). Clinic counts of 
returned applicators, considered to be objective, are easily incorporated into clinic procedures at 
minimal extra cost, but are also subject to numerous forms of bias, and counts of returned empty 
applicators may overestimate adherence when used as primary proxies for adherence (9, 12). 
Biologic or surrogate markers such as applicators tests may be relatively inexpensive and easy to 
implement in clinical trial settings, enabling optimisation of adherence during trial conduct and 
providing another measure of study product adherence. However, the utility of dye-stain assay (DSA) 
is limited in terms of accuracy of assessing polypropylene applicators commonly used in recent 
microbicide trials, and concerns regarding the safety of some dyes (6, 13). 
 
In CAPRISA 004, an applicator test coined the Visual Inspection of Returned Empty Applicators 
(VIREA) examined applicators under ambient light for residue on the outside of the applicator as an 
indicator of vaginal insertion, and identified about 16% less product adherence as compared to 
participant self-report (12). VIREA also enabled identification of participants with potential adherence 
challenges at their clinic visit. Visual inspection of returned empty applicators under 365 – 385nm 
ultraviolet (UV) light for evidence of vaginal insertion has also been used as an adherence 
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measurement method, with some studies suggesting UV assessments should be considered an 
objective measure of product use in future microbicide trials (14). Various studies of methods used to 
measure adherence have shown UV Light assessment of empty hydroxyethyl cellulose (HEC) 
placebo applicators inserted vaginally on a daily basis or pericoitally performs as well or better than 
other applicator tests, with higher sensitivity of UV light assessment both with prior gel dosing and 
post-sex application (15-17). Little is known about the technique in assessing empty TFV gel 
applicators in a clinical trial setting using a coitally-dependant dosing strategy.  
 
This study aims to assess the accuracy of visual inspection and UV light inspection by calculating the 
sensitivity and specificity of the methods in a pilot assessment of control applicators, and furthermore 
to compare the techniques for reliability and concordance in a subset of empty TFV gel applicators 
returned as used in an implementation-effectiveness trial. The purpose of this study was to ascertain 
whether assessment of applicators under UV light can be considered a more accurate and less 
subjective measure of product adherence than VIREA. 
 
METHODS  
CAPRISA 008 Tenofovir Gel Implementation trial, was an open-label randomized controlled trial to 
assess the implementation effectiveness and safety of TFV gel provision through family planning (FP) 
services in KwaZulu-Natal, South Africa, which also provided post-trial access of TFV gel to HIV-
uninfected women who previously participated in CAPRISA 004. CAPRISA 008 was conducted at the 
urban eThekwini and rural Vulindlela CAPRISA Research Clinics that participated in the CAPRISA 004 
study and their neighbouring public sector primary health care (PHC) clinics where FP services are 
provided in KwaZulu-Natal, South Africa (18). Eligible women were randomly assigned to receive their 
TFV gel either through FP services coinciding with their contraceptive schedule (intervention arm), or 
monthly though the CAPRISA research clinics (control arm). 
 
As in CAPRISA 004, the CAPRISA 008 study protocol required women to insert one dose of 1% TFV 
gel within 12 hours before sex and a second dose of gel as soon as possible within 12 hours after sex 
and no more than two doses of gel in a 24 hour period (BAT24) (2, 18). Study product was issued in 
quantities sufficient to cover their needs until their next scheduled visit according to their reported 
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frequency of sexual acts. Women were issued opaque resealable plastic bags to hygienically store one 
used empty applicator per bag until their return to the clinic. They were required to return all unused 
and used/empty applicators to the pharmacy for reconciliation at each study visit (two – three monthly 
according to contraceptive schedule at the FP clinic, or monthly at the CAPRISA clinic), or more 
frequently if required. Applicators assessed were a subset of empty applicators returned as used to 
the CAPRISA Vulindlela Research Clinic pharmacy in the CAPRISA 008 trial. 
 
Pharmacy staff were trained in the technique of assessing returned empty applicators by visual 
inspection by the CAPRISA 004 Vulindlela clinic gel assessor, and in the technique of UV light 
inspection, and had to qualify as an assessor by scoring 100% on both a VIREA and a UV Light 
proficiency test.  
 
Applicators were independently assessed by each technique according to standard procedures and 
pre-defined criteria for inspection (table 1) so that assessment outcomes by one technique did not 
influence the other. VIREA preceded UV light assessments, and every effort was made to minimise 
contamination of the returned empty applicators between these assessments. This included only 
handling applicators with gloves by the ribbed end of the barrel, and carefully inserting the applicators 
back into their numbered resealable plastic bags post assessment. 
 
The criteria for assessing empty TFV gel applicators by VIREA (table 1) were as per those utilised in 
CAPRISA 004 (12) (figures 1a-c). The procedure involved inspecting the barrel of each empty 
applicator under ambient light for evidence of vaginal insertion. If the barrel appeared clean, the cap 
was removed and the applicator tip was inspected. Applicators with no visible residue of any kind on 
barrel and a clean tip were assessed as “appears unused”.  A viewing box, based on that proposed 
by Moench et al (16), was utilised to view the returned empty applicators under UV illumination. UV 
light was provided by a UVL-21 Compact UV Lamp (365-nm). Applicators were viewed through a 76- 
x 102-mm Tiffen UV Haze-2A filter to block transmission of reflected source illumination. The criteria 
for assessing empty applicators by UV light (table 1) were as suggested by Moench et al (16), where 
those applicators with a streaked pattern of blue-green fluorescence, predominantly from adherent 
vaginal fluids, were scored as positive for evidence of vaginal insertion and assessed as “appears 
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used” (figure 1d). To accommodate assessment of those applicators which may have been wiped by 
participants post insertion, an additional category of “appears possibly used” (applicators with a 
generalised fluorescence) was included in the criteria for UV light assessment (figure 1e).  
 
To determine the sensitivity and specificity of the two assessment methods, a small sample of 12 
applicators that were known to be vaginally inserted (positive controls) and 12 sham applicators that 
had gel expelled ex-vivo, handled, but not vaginally inserted (negative controls) were independently 
assessed by a blinded primary assessor using VIREA and then UV Light inspection at time point one 
(120 days after receipt of applicators at the pharmacy). After storage at controlled room temperature 
for a further three months, the same sample was reassessed to determine if storage had any effect on 
the sensitivity and specificity of the adherence measures. The positive controls for this pilot 
assessment were provided by volunteers within the CAPRISA 008 study, who inserted either their 
before sex or after sex gel dose under direct observation in the research clinic.  
 
To better understand the concordance of the two techniques, VIREA and UV light inspection was also 
performed on the empty TFV gel applicators returned over a selected one-month period (05 – 29 
January 2015) by those participants who were enrolled in the CAPRISA 008 trial at the Vulindlela 
Research Clinic. To evaluate the reliability of the assessment criteria, assessments were performed by 
two independent assessors, however only the assessment outcomes of the primary assessor were 
considered for the interpretation of concordance of the techniques. For the purpose of this study and 
for more accurate comparison with VIREA technique, applicators assessed as “appears possibly 
used” by UV light were considered to be “appears used”. 
 
Descriptive statistics were used to describe the baseline and behavioural characteristics of the 
women whose applicators were assessed. Sensitivity and specificity as well as 95% confidence 
intervals for these were calculated by standard methods. Analysis using percent agreement and the 
Kappa statistic was performed to assess interrater (inter-assessor) reliability as well as reliability of 
the assessment techniques. Statistical analysis was performed using IBM SPSS Statistics Version 23. 
The University of KwaZulu-Natal’s Biomedical Research Ethics Committee reviewed and approved 





The CAPRISA 008 trial enrolled a total of 382 participants across the CAPRISA eThekwini and 
CAPRISA Vulindlela sites, with 266 of these enrolled at the CAPRISA Vulindlela Research Clinic 
where this study was undertaken. During the month of January 2015, a total of 146 women were seen 
for 152 follow-up visits at the Vulindlela Research Clinic. Of these, two were on product hold due to 
pregnancy, two reported either lost gels or leaving their gels at home, and 27 returned only unopened, 
unused applicators. The 115 participants who had reported gel usage since their previous study visit 
returned a total of 1880 applicators, of which 1316 were returned empty as used, and 564 returned 
unopened as unused.   
 
The baseline and behavioural data of these 115 participants show the median age to be 28 years, 
with 100 (87%) women reporting to be in a stable relationship, and 15 (13%) women married (table 2). 
At their visit in January 2015, 108 (95.6%) women reported using gel at their last sex act as per 
BAT24 instructions.  
 
Sensitivity and Specificity of techniques 
At the 4-month assessment of the positive and negative controls, both the sensitivity (83.3% vs. 
75.0%) and specificity (91.7% vs. 66.7%) of assessment by UV light was higher as compared to that 
of the technique of VIREA. After storage for a further 3 months, the assessments showed similar 
results, with sensitivity and negative predictive value (NPV) for both methods increasing to 100%. The 
specificity decreased for both methods (table 3). 
 
Concordance of techniques  
Substantial inter-assessor agreement for both VIREA and UV light techniques is evident in the 
percentage agreement (85.0% and 78.6% respectively) and, is supported by the kappa statistic, 
confirming reliability of the assessment criteria by each technique (table 4).  
 
The assessment outcomes by the primary assessor showed 78.8% agreement between the two 
assessment techniques (Kappa statistic calculated as 0.529 (p<0.001), 95% CI 0.484-0.574). Of the 
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983 applicators assessed as used by VIREA, 747 (56.8%) were assessed as used or possibly used 
by UV light inspection. Assessments by VIREA and UV light concurred that 290 (22%) of the returned 
empty applicators did not have any visual evidence of vaginal insertion, and may not have been 
inserted into the vagina. In addition, 236 of the 983 applicators assessed as “appears used” by VIREA 
did not have any evidence of vaginal insertion by UV light inspection, and were classified as “appears 
unused” (table 5). UV light assessment identified a total of 526 applicators as unused. This, added to 
the 30% (564/1880) unopened applicators returned as unused, potentially increases the proportion of 
unused applicators to 58%, suggesting 28% less product used as compared to that returned as used 
by this subset of participants in January 2015. 
 
On average it took the primary assessor less than 30 minutes to assess 100 empty applicators, 
irrespective of the measurement method employed. 
 
DISCUSSION 
Preliminary investigations into UV light assessment of empty TFV gel applicators returned as used 
suggests that the technique may be a more reliable measure of microbicide gel adherence and a less 
subjective measure as compared to the technique of VIREA. Inspection by UV light identified 526 of 
all returned empty applicators that may not have been inserted vaginally – this is about 28% less 
product used as compared to that returned as used by this subset of women. 
 
The higher sensitivity and specificity of UV light assessment as compared to VIREA at 4-month 
assessment is similar to findings of other studies assessing empty HEC placebo applicators (16, 17), 
and suggests that the UV light assessment technique is more likely to correctly identify used empty 
applicators as used, and unused empty applicators as unused, and may be more accurate as an 
adherence measurement method than the VIREA assessment technique. Results showed that after 
three months of storage the accuracy of the techniques seemed similar, with the sensitivity and NPV 
increasing and the specificity decreasing for both techniques. This is in contrast to findings of a study 
that assessed the effect of storage after 30 days on assessment outcomes, where both the specificity 
of visual inspection and the sensitivity of UV light inspection showed a statistically significant increase 
(17). In our study, we would expect the specificity of the techniques, particularly VIREA, to decrease 
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with time due to possible contamination resulting in more false positives, especially since the same 
sample was assessed at each time point. The increased sensitivity may be attributed to the 
experience gained by the assessor who assessed the bulk of the applicators (n=1316) between the 3- 
and 7-month sensitivity and specificity assessments.  
 
Previous findings in a substudy of CAPRISA 004, where 22.5% of applicators assessed by VIREA 
appeared not to have any visual evidence of vaginal insertion, lead authors to conclude that 
estimations of product adherence based solely on counts of returned empty applicators without 
VIREA may be over-estimates (12). Similarly we found that independent assessments by VIREA and 
UV light concurred that 22% of all returned empty applicators assessed appeared unused. In addition, 
UV light assessment identified another 18% of all returned empty applicators assessed, that were 
assessed as used by VIREA, which may not have been vaginally inserted. Given the higher specificity 
and NPV of UV light assessment found initially in our pilot sample, this points to the subjective and 
forgiving nature of the VIREA technique and suggests that VIREA may also overestimate actual 
product usage as compared to UV light inspection. 
 
A study of DNA/protein biomarkers found these assays to be highly sensitive and specific in detecting 
vaginal insertion; however, these assays are both more costly and labour intensive than UV light 
assessment (17). Combining UV light assessment of all returned empty applicators, followed by 
further evaluation of those applicators appearing unused and possibly used using DNA and protein-
based methods may increase the accuracy of adherence measurement whilst minimizing costs.  
 
Assessment of returned empty applicators by UV light inspection is a relatively quick and simple 
method of measuring adherence to microbicide gel applicators. It can easily be incorporated into clinic 
flow to allow for real-time feedback of product use adherence that could be utilised to direct targeted 
adherence interventions. UV light inspection may not be as accurate as measured drug level 
concentrations, but offers the benefit of real-time understanding of product use. In cases where 
fluorescent properties of the candidate microbicide gel and placebo gel are similar, the method also 
lacks the risk of unblinding during follow-up especially if performed by pharmacy staff who are often 




There was no difference in the time taken to assess applicators by either method. However, the 
apparatus used for UV light assessments allowed for only one applicator to be viewed at a time. This 
is in stark contrast to work by Moench et al, where readers were able to read a set of applicators by 
UV light in half the time taken to read the set by ambient light; however, apparatus used by Moench et 
al allowed for rapid viewing of all portions of multiple applicators at a time (16).  
 
Several limitations make extrapolating the finding of this study challenging. The sample size in this 
pilot assessment of sensitivity and specificity is small and limits it interpretation. Due to the limited 
number of positive controls collected (n=12), the same sample of applicators had to be utilised for 
sensitivity and specificity analysis at 4-months and at 7-months. We cannot be sure that potential 
accidental contamination of the sample at initial assessment did not influence the outcome of 
assessment after an additional 3 months of storage. None of the currently used adherence 
measurement methods in microbicide trials are able to accurately measure actual product use (timing 
of product use in relation to sexual activity and HIV exposure nor the amount of product actually used) 
and assessment by VIREA and UV light are no exceptions. Unbiased and acceptable methods of 
measuring timing of gel use relative to sexual activity in microbicide trials are lacking and warrant 
further investigation. In addition, the practice of washing vaginal secretions off the used empty 
applicators may limit the accuracy of both methods of assessment, but adequate counselling against 
this practice may overcome this challenge. Moreover this was a substudy within an existing 
implementation trial nearing study close, and due to time constraints was not designed to capture all 
the data required to fully appreciate the value of the technique in assessing returned empty TFV gel 
applicators. 
 
Although UV light assessment has been shown to be a feasible surrogate marker of product 
adherence, it would be pertinent for future studies planning to utilise UV light inspection to validate the 
measure against an available biomarker, and to investigate the fluorescent properties of the 
microbicide product under investigation so as to fully understand its potential to quench cervicovaginal 
fluid (CVF) fluorescence or lead to unblinding in a blinded placebo-controlled study. A larger study to 
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assess accuracy of the method, the impact of gel dosing on the technique and validation of the 
technique using biomarkers is warranted. 
 
It is recommended that UV light assessment be used as part of a triangulated approach to measuring 
product adherence, possibly in conjunction with a DNA/protein biomarker test to verify assessment 
outcomes for applicators assessed as unused or possibly used, both to improve the accuracy of 
adherence data collected and to overcome the limitations associated with any single adherence 
measurement method.  
 
In conclusion, assessment by UV light identified 40% of returned empty applicators as appearing not 
to be used, translating to 28% less product used as compared to that returned as used by this subset 
of women. The technique, used as a rapid on-site assessment of microbicide gel adherence, will aid 
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Figure 1: Applicators as viewed under ambient light (a-c) and under 365nm UV light (d-f).  
By VIREA, Figures 1a-c were assessed as appears used. By UV light, Figure 1d was assessed as 









 Appears used Appears possibly used  Appears unused 
VIREA  Any visible residue, 
mucus, gel, secretions or 
hair on barrel 
Any discolouration or 
residue that was not gel 
on tip under cap 
N/A No residue of any kind on 
barrel, clean tip or only 
clean gel visible on tip 
UV Light Streaked pattern of blue-
green fluorescence on 
barrel 
Generalised fluorescence 
on barrel, with or without 
fluorescent speckles 
No streaked or 
generalised fluorescence 




Table II: Baseline and behavioural data, January 2015, n = 115 
Baseline data   
Age, median (IQR) 28 (24-31) 
Total sex partners since sexual debut, 
median (IQR) 
2 (1-3) 
Sex acts last 30 days, median (IQR) 4 (2-6) 
Relationship status (n, %)  
Married 15 (13.0) 
Stable 100 (87.0) 
Follow-up data, January 2015  
Sex acts since last visit, median(IQR)* 5 (3-7) 
Sex acts last 30 days, median(IQR)* 4 (2-5) 
Gel use last sex act (n, %)*  
No gels used 5 (4.4) 
BAT 24 108 (95.6) 
 
IQR: Interquartile range, BAT24: One gel up to 12 hours Before sex, one gel as soon as possible but with 12 hours After sex, 






Table III: Sensitivity and Specificity of VIREA and UV light assessments 
 VIREA 4 months VIREA 7 months UV Light 4 months UV Light 7 months 
 % 95% CI % 95% CI % 95% CI % 95% CI 
Sensitivity 
 Positive controls (n =12) 75.0 42.8-94.5 100 73.5-100 83.3 51.6-97.9 100 73.5-100 
Specificity 
 Negative controls (n =12)  66.7 34.9-90.1 58.3 27.7-84.8 91.7 61.5-99.8 66.7 34.9-90.1             
         
PPV 69.2 38.6-90.9 70.6 44.0-89.7 90.9 58.7-99.8 75.0 47.6-92.7 
NPV 72.7 39.0-94.0 100 59.0-100 84.6 54.6-98.1 100 63.1-100 
 
CI: Confidence Interval 
Sensitivity (%) = 100 x true positive / (true positive + false negative), Specificity (%) = 100 x true negative / (true negative + 
false positive) 
PPV: Positive predictive value, (%) = 100 x true positive / (true positive + false positive), NPV: Negative predictive value, (%) = 







Table IV: Analysis of Inter-assessor agreement, n = 1316 
 VIREA UV Light Inspection 
Agreement, % 85.0 78.6 
Kappa Measure of agreement 













Table V: Comparison of assessment outcomes, n = 1316 
  UV Light % (n) 








VIREA % (n) Appears used 46.3 (455) 29.7 (292) 24.0 (236)  74.7 (983) 
Appears possibly used - - - - 
Appears unused 0.6 (2) 12.3 (41) 87.1 (290) 25.3 (333) 
Total 34.7 (457) 25.3 (333) 40.0 (526) 100 (1316) 
*For comparison with VIREA assessment outcomes, those applicators assessed as appears possibly used by UVL were 
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CHAPTER 4: OVERALL DISCUSSION 
 
4.1 Discussion of major findings 
The purpose of this study was to investigate and compare the techniques of VIREA and UV light 
inspection of empty TFV gel applicators to better understand the utility of these techniques as 
adherence measurement methods. Utility was assessed in terms of accuracy (sensitivity and 
specificity), reliability and concordance (verifying the assessment criteria, and investigating 
agreement), and practicality (time and feasibility). This research project was driven by the question as 
to whether UV light assessment of empty TFV gel applicators was comparable, or perhaps even less 
subjective, than assessment by VIREA.  
The manuscript (chapter three) meets the four objectives as listed in the introduction chapter (chapter 
one) of this dissertation. 
4.1.1 Objective 1: To undertake a pilot study to estimate the accuracy of both VIREA and UV light 
assessments of empty TFV gel applicators by calculating the sensitivity and specificity of the 
techniques at time point one (within four months of applicator receipt). 
Time point one assessment found sensitivity and specificity of VIREA to be 75.0% and 66.7% 
respectively, and sensitivity and specificity of UV light to be 83.3% and 91.7% respectively. 
Both the sensitivity (83.3% vs. 75.0%) and specificity (91.7% vs. 66.7%) of assessment by UV light 
was considerably higher as compared to that of the technique of VIREA. The higher sensitivity and 
specificity of UV light assessment at the time point one assessment is similar to overall findings of 
other studies that compared these measurement methods by assessing empty HEC placebo gel 
applicators (12, 13).  Moench et al. found the sensitivity and specificity of UV light inspection (84% 
and 83% respectively) to be higher than visual inspection (76% and 63% respectively) (12). Thurman 
et al. found higher sensitivity of UV light as compared to visual inspection at 7-day assessments 
(74.2% vs. 54.4% respectively) and at 30-day assessments (92.2% vs. 51.9% respectively) (13). 
Although these assessments were performed at different time points as compared to our study, 
collectively these findings suggest that the UV light assessment technique is more likely to correctly 
identify used empty applicators as used, and unused empty applicators as unused, and may be more 
accurate as an adherence measurement method than the VIREA assessment technique. 
4.1.2 Objective 2: To assess the effect of storage on the sensitivity and specificity of the two 
techniques performed on the same set of applicators at time point one and two (after an additional 
three months of storage). 
Time point two assessment found sensitivity and specificity of VIREA to be 100% and 58.3% 
respectively, and UV light to be 100% and 66.7% respectively. 
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After storage at controlled room temperature for three months, the time point two assessments showed 
increased sensitivity for both methods, with decreased specificity. The increased sensitivity may be 
attributed to the experience gained by the primary assessor who assessed the bulk of the applicators 
between the 3-and 7-month sensitivity and specificity assessments. Our time point two analysis, at 7-
months post receipt of applicators, suggests the techniques are not very different in terms of accuracy. 
These findings are in contrast to findings of a study that assessed the effect of storage after 30 days on 
assessment outcomes, where both the specificity of visual inspection and the sensitivity of UV light 
inspection showed a statistically significant increase (13). However, this study used two different sets 
of applicators for assessment at 7- and 30-days, whereas we used the same set of applicators that were 
assessed at time point one for the time point two assessment. We suspect that possible contamination 
of the sample applicators as well as experience gained by the primary assessor between the two 
assessment time points may have influenced our results. 
 
4.1.3 Objective 3: To assess the reliability and concordance of UV light assessment of a subset of 
returned used / empty TFV gel applicators in a select one-month period for agreement, with the 
VIREA assessment of the same applicators, in terms of evidence of vaginal insertion. 
Results of assessment outcomes of the 1316 returned empty applicators by the two assessors 
(appendix K), showed substantial inter-assessor agreement. This is evidenced in 85% agreement for 
the VIREA technique (Kappa statistic calculated as 0.627 (p<0.001), 95% CI (0.580, 0.674), and 
78.6% agreement for the UV light technique (Kappa statistic calculated as 0.676 (p<0.001), 95% CI 
(0.643, 0.709). These results confirm the reliability of the assessment criteria for each technique.  
 
Our assessment criteria for VIREA technique were based on those defined in the previous study of 
VIREA of empty TFV gel and placebo gel applicators, since this study was able to validate the 
technique by linking assessment outcomes with detectable TFV levels in a subset of women 
randomized to the TFV gel arm in CAPRISA 004 TFV Gel Efficacy trial. The assessment criteria for 
UV light assessment of empty TFV gel applicators was based on those used by Moench et al. with the 
added category of “appears possibly used” to accommodate for the possible wiping of applicators 
after use. It is possible that applicators assessed as “appears possibly used” by UV light may have 
been pre-sex applicators which have been shown to have a lower signal intensity, especially when 
viewed under 385nm UV light source (12). For the purpose of this study and for more accurate 
comparison with VIREA technique, applicators assessed as “appears possibly used” by UV light were 
considered to be “appears used”.  
Although we do not actually know how many of the empty applicators returned as used were actually 
used, concordance of the techniques, as per assessment outcomes of the primary assessor, was 
demonstrated by 78.8% agreement between the two assessment techniques (Kappa statistic calculated 
49 
 
as 0.529 (p<0.001), 95% CI (0.484, 0.574). Of the 983 applicators assessed as used by VIREA, 56.8% 
were assessed as used or possibly used by UV light inspection. Assessments by VIREA and UV light 
concurred that 22.0% of the 1316 empty applicators returned as used appeared not to have been used. 
Similarly, the previous study of VIREA in CAPRISA 004 TFV gel efficacy trial found 22.5% of 
applicators assessed appeared not to have been inserted vaginally (10). These findings suggest that 
measurement of product adherence should include a physical verification of returned empty 
applicators to obtain a more reliable estimate of adherence than self-report or product count alone.   
Amongst the 21.2% disagreement between the techniques are two interesting points. Firstly, only 
12.9% of the 333 applicators assessed as unused by VIREA were assessed as used / possibly used by 
UV light. This suggests that applicators assessed as unused by VIREA are most likely to be unused. 
Secondly, 24.0% of 983 applicators assessed as “appears used” by VIREA did not have any evidence 
of vaginal insertion by UV light inspection, and were classified as “appears unused”. This is 
potentially another 18.0% of applicators that may not have been used, over and above the 22.0% that 
assessment by both methods agreed were unused.  
 
Overall assessment by UV light identified 526 of the 1316 returned empty applicators as having no 
evidence of vaginal insertion. Adding this to the 30.0% (564/1880) unopened applicators returned as 
unused in January 2015, potentially increases the proportion of unused applicators to 58.0%, 
suggesting 28.0% less product used as compared to that returned as used by this subset of women. 
 
Reliability and concordance of the techniques were assessed on average about seven months after 
receipt of the returned empty applicators. This informed the choice of the time point two assessment 
period for sensitivity and specificity. 
 
4.1.4 Objective 4: To measure the time taken to assess a set of returned used / empty applicators for 
each technique in order to evaluate the practicality and efficiency of the measurement methods. 
On average it took the primary assessor about 30 minutes to assess 100 empty applicators, irrespective 
of the measurement method employed (30 minutes 29 seconds for VIREA and 29 minutes 30 seconds 
for UV light). This is in sharp contrast to research by Moench et al. which also compared reading 
times for the methods assessed. Moench et al. found the mean reading time to read the full set of 250 
applicators was only 15 minutes for UV light assessment and 32 minutes for ambient light 
assessment. However, this rapid assessment rate was possible because the UV viewing box utilised by 
Moench et al. allowed for loading of 36 applicators onto a tray which was slid over rails into the 
viewing box allowing for multiple applicators to be viewed at a time (12). This discrepancy between 
our findings and those of Moench et al. is expected since the visual inspection technique and the 
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viewing box to view applicators under UV light utilised in our research project allowed for viewing of 
only one applicator at a time. 
 
This research project found that with training, assessments using VIREA and UV light were easy to 
perform. They could easily be incorporated into the clinic flow, and since counts of returned 
applicators are an integral part of study product accountability, applicator assessments are best 
performed by trained pharmacy staff.  
 
 
4.2 Study limitations 
This was a substudy within an existing implementation trial nearing study close, and due to time 
constraints was not designed to capture all the data required to fully appreciate the value of the UV 
light technique in assessing returned empty microbicide gel applicators. For optimal benefit of UV 
light assessment, these should be performed in real-time at the clinic visit so as to be able to inform 
targeted adherence interventions in those women identified as having difficulties with adherence. We 
were unfortunately not able to perform the assessment of reliability and concordance in real-time. 
 
Several limitations should be considered when interpreting the results of this study. Due to the limited 
number of positive (known to be vaginally inserted) controls collected, the sample size in the pilot 
assessment of sensitivity and specificity is small, and the same set of applicators had to be utilised for 
sensitivity and specificity analysis at time point one and after storage for three months at controlled 
room temperature at time point two. We cannot be sure that accidental contamination of the sample at 
initial assessment did not influence the outcome of time point two assessments, and suspect this may 
have been the reason for decreased specificity of the methods after storage (more false positives).  
As is the case with many of the other currently used adherence measurement methods, applicator tests 
are not able to accurately measure actual product use (timing of product use in relation to sexual 
activity and HIV exposure, nor the amount of product actually used or whether it was expelled ex-
vivo prior to vaginal insertion of the applicator).  
In an attempt to accommodate the practice of wiping applicators after use and before return to the 
clinic, we included an “appears possibly used” category for UV light assessment; however, the 
practice of washing vaginal secretions off the used empty applicators may limit the accuracy of both 
methods of assessment. Participants need to be adequately counselled to discourage these practices.  
Validation of the techniques against biomarkers or detectable TFV in CVF may have strengthened the 
findings of this research project, however was not possible due to time and funding constraints. A 
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larger study to assess accuracy of UV light assessment, the impact of gel dosing on the technique and 
validation of the technique using biomarkers is warranted.  
 
4.3 Recommendations for future research  
UV light assessment should be considered in conjunction with other adherence measurement methods 
as part of a triangulated approach in future clinical trials of vaginal microbicide gels. However, it is 
essential to fully investigate the fluorescent properties of the microbicide product under investigation 
so as to fully understand the potential to quench CVF fluorescence or lead to unblinding in a blinded 
placebo-controlled study.  
The challenge of low adherence in phase II trials assessing efficacy of a candidate microbicide needs 
to be addressed. Optimising adherence during trial conduct is one possible solution. Despite reported 
high gel acceptability and intensive adherence support strategies based on motivational interviewing 
techniques, about 40% of the women enrolled in CAPRISA 004 TFV Gel Efficacy trial were only 
able to use the gel for less than 50% of their sex acts (3). Careful consideration of the social and 
behavioural factors, such as risk perception, partner influence on use and effect of unknown efficacy 
on use-adherence, that impact adherence are critical (2). In addition, early identification of women 
with potential adherence challenges during the trial may enable targeted adherence interventions to 
encourage correct and consistent product use. An adherence measurement method that can serve the 
dual purpose of assessing product adherence in real-time whilst contributing to overall estimation of 
product adherence is an important consideration in microbicide clinical trials. A study comparing two 
applicator tests (DSA and UV light assessment) with Wisebag and self-reported adherence, found 
14% and 16% disagreement between readers for DSA and UV assessment respectively, especially for 
negative control applicators. This unexpectedly high number of indeterminate results led the authors 
to suggest UV assessment of all applicators, followed by DSA only on those applicators deemed 
indeterminate by UV assessment (14). Another study has found DNA/protein biomarkers to have high 
sensitivity and specificity (98.3% and 100%) at both 7- and 30-day assessments (13). However, these 
biomarker tests are expensive. Combining UV light assessment of all returned empty applicators, 
followed by further evaluation of those applicators deemed “appears unused” and “appears possibly 
used” using DNA and protein-based methods to both increase the accuracy of real-time adherence 
measurement whilst minimizing costs, will allow for immediate feedback to direct adherence support 
interventions. This approach is recommended as a rapid on-site assessment of product adherence to 
identify women with challenges to adherence at their clinic visit, inform interventions to optimize 
adherence during the trial, contribute to accurate assessment of overall study product adherence, and 




The utility of UV light assessment of other vaginally inserted microbicide formulations, such as 
vaginal rings, should also be explored further.  
 
4.4 Concluding statements 
Assessment by UV light identified 40% of returned empty applicators did not appear to be used, 
translating to potentially 28% less product used as compared to that returned as used by women. The 
preliminary sensitivity and specificity of the technique in assessing empty applicators returned as used 
suggests UV light assessment is both a more accurate and less subjective measure of adherence as 
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APPENDIX A: Literature review summaries 
Literature review: Methods of Measurement 
Studies comparing multiple methods of measurement 
Authors, 
year 
Study design Findings Comments / Conclusions / Recommendations 
Visual Inspection Ultraviolet light DSA MEMS-type Other 




Assessment of 95 reported 
pre-sex and 95 reported 
post-sex HEC placebo 
applicators by 3 readers 
Applicator: LDPE 
Microlax®-type;  
Dosing: pre- and post-sex 
twice a week for 3-4 weeks 
Not assessed Streaked or 
speckled pattern of 
blue-green 
fluorescence 
(single spotlight 60 x 
385nm UV wide 










100% Post-sex 90% 
Specificity: Pre-sex 
and Post-sex 100% 
Not assessed Not assessed Small study; both DSA & UV: reliable biomarker with 
pericoital BAT-24 dosing; non-invasive, require little 
time, inexpensive, easy to perform, easily incorporated, 
real-time feedback to address behavioural challenges; 
Inter-reader agreement higher on pre-sex for DSA, and 
lower for post-sex as compared to UV; larger studies & 
high-risk cohorts needed 




Evaluated 4 methods of 
assessment of 250 (170 
known inserted / 80 sham-
inserted) HEC placebo 
applicators: inspection under 
ambient light, UVL, and 
DSA with Alcian Blue and 









and / or gel) 
Sensitivity: 76% 
Specificity: 63% 
Reading time: 32 
mins for 250 apps 
Streaked pattern of 
blue-green 
fluorescence 





without prior gel 
applications, 
increasing to 95% in 
applicators inserted 
after previous gel use 
(statistically 
significant) 
Reading time: 15 




Reading time: 26 




Reading time: 63 
mins for 250 apps 
 
MEMS cap on 
container for storing 
+/- 60 applicators: 
data matched written 
records to within 2 
minutes 
Not assessed Concern that without prior gel applications accuracy of all 
4 methods in coital dosing may be limited; increased 
accuracy after prior insertions possibly due to 
accumulated gel from prior doses, allowing for retention 
of more gel, mucous and cells on applicator; MEMS and 
UV inspection should provide fast, reliable, quantitative 
adherence assessment in daily dosing regimens 
Van der 
Straten A 





Compared 872 returned 
empty applicators (plus 39 
known inserted and 43 
emptied ex-vivo applicators 
for sensitivity and 
specificity) HEC placebo 
applicators by DSA, UV 
light assay, Wisebag® and 
self-report: 2 readers 
Not assessed Streaked pattern of 
blue-green 
fluorescence 
(single 60 x 385nm 











Wisebag® used as 
passive monitoring; 





useful as visual cue  
to remind of gel 
Self-report at study 
exit: 
Retrospective 
assessment: days with 
missed doses, 6-point 
Likert scale assessing 
frequency of gel 
insertion;  
DSA and UVA simple & inexpensive, UVA faster as no 
dye-drying time required; UVA provides immediate 
adherence feedback during study visits; neither test is 
“anatomically specific” i.e. unable to determine actual 
vaginal insertion; consider UVA on all applicators 
followed by DSA on indeterminate applicators; 
techniques require further evaluation: for pericoital and 
daily dosing regimens; with polypropylene apps; also for 
rectal dosing regimens; Wisebag acceptable but 
57 
 
Studies comparing multiple methods of measurement 
Authors, 
year 
Study design Findings Comments / Conclusions / Recommendations 
Visual Inspection Ultraviolet light DSA MEMS-type Other 
Applicator: LDPE 
Microlax®-type;  
Dosing: daily over 30 days; 
8% disagreement 
between readers 
dosing, 18% said 
impractical or lacked 
discretion; 
underestimated adherence; Reasons for not opening every 
day: forgetting, traveling, not returning home / returning 
late; MEMS adapted devices useful as adherence-
enhancing tools especially if integrated SMS reminders;  
Thurman AR 
et al, 2014 
 
(13) 
Compared 240 (and 
additional 240 at 30 days) 
Visual and UV light 
inspection of HEC placebo 
filled applicators with 
DNA/protein biomarkers at 
2 time points (7 days and 30 
days): 3 readers 
Applicators: HTI 
polypropylene;  
Dosing: all 12 applicators 

























Analysed sensitivity per subgroup: all, all except wiped, 
no gel present, gel present, wiped; overall higher 
sensitivity of UVL at 30 days attributed to increased 
sensitivity of detecting wiped applicators; DNA/protein 
biomarkers more sensitive and specific in all subsets as 
compared to VIRA at days 7 and 30 (statistically 
significant); DNA and protein biomarkers overall higher 
sensitivity and specificity than UVL at days 7 and 30 
(statistically significant), but expensive and labour 
intensive; both visual applicator tests easily performed on-
site, inexpensive, need little ancillary equipment; but are 
still subjective assessments!, prone to Inter-reader 
variability; UVL assessment is low cost, with improved 
sensitivity and specificity after storage, but found 
significant IRV at both time points 
 
Studies assessing a single method of measurement 
Authors, year Study design Methods & Findings Comments / Conclusions / Recommendations 




Visual Inspection of 59 
800 returned empty 
applicators (1% 
tenofovir gel and HEC 
placebo) within 




VIREA visual assessment under ambient light according to predefined criteria: “appears used” or “appears unused” 
Appears used:77.5% 
Appears unused: 22.5% 
Identified about 16% more applicators with no visual evidence of vaginal insertion than that reported used by 
women 
Validated using tenofovir detected in CVF at 375 matching study visits: TFV detected in CVF in only 13.5% of 
women who had ≤50% of empty applicators categorised as “used” by VIREA in contrast to 58.3% of the women who 
had >50% of empty applicators categorised as “used” by VIREA (Limitation: TFV only detected in vagina for short 
time after use – hence expect lower correlation between proportion of appearing used with vaginal TFV 
concentrations) 
Estimating adherence by physical count of returned empty 
applicators without visual inspection may over-estimate; real-
time identification of applicator mechanics issues; Technique is 
subjective despite standardised process Physical verification aids 
understanding of adherence and identifies participants with 
potential adherence challenges 
van der Straten 




and acceptability of 
Wisebag® in a 3-armed 
double-blind pilot study 
(n=50) 
Wisebag® - opened daily for 14 days, take study sticker from bag and place sticker on to diary card; day one at clinic 
under direct staff observation, day 14 Wisebag returned and data downloaded; quantitative: behavioural and 
acceptability questionnaire; qualitative: interview using semi structured guide to assess experience and attitude towards 
Wisebag and study procedures 
Randomised 2:2:1 to Online (events transmitted real-time via cellular signal); Offline (events stored in device 
memory); or Inactive (“dummy” devices) 
By electronically recorded events: 26% adherent to once-day opening instructions (in contrast to 46% per diary 
card and 48% by self-report) 
22% opened Wisebag >1x per day (“curiosity events”)  
94% liked using the Wisebag, and almost 94% liked overall appearance 
Short duration, no study product, lacks other objective measures 
to validate event data; 
Wisebag seemed feasible, acceptable technology with potential 
for as adherence measure for microbicide trials; data should be 
validated using actual products, with and without SMS 
notifications, and with biomarkers 
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Studies assessing a single method of measurement 
Authors, year Study design Methods & Findings Comments / Conclusions / Recommendations 





gel use with Wisebag® 
in CAPRISA 004 
(n=10) 
Wisebag® - Pilot study of microbicide use within CAPRISA 004 with up to 4 months follow up; included SMS 
reminders of dosing regimen; opening events compared with self-reported sexual activity & applicator returns; over 33 
monthly follow-up visits 47.8% of recorded opening events matched number of returned empty applicators; 
discrepancies postulated to be due to “pocket dosing” 
Small study; challenges with interpreting event-data to self-
reported gel use; concerns for possible social harms with SMS’s 
proved unfounded 









0.05% FD&C Blue Dye No. 1 solution, 3 evaluators 
Sensitivity for known single-use applicators: 81-95% 
Specificity for unused applicators: 86-93% 
Sensitivity by DSA for applicators inserted twice daily x 14 days: 47-77%, but 168/169 had vaginal epithelial cells by 
Gram stain 
Sensitivity varied widely depending on evaluator and prior gel 
exposure; Sensitivity decreased with multiple gel applications; 
authors cannot recommend DSA of HTI polypropylene 
applicators as adherence monitoring tool 




Validation of DSA of 




Applicators stained with 0.05% FD&C Blue No. 1 Granular Food Dye for 5 seconds; assessed by 4-6 readers 
Experiment 1 (validate DSA): 132 applicators read by 5 readers - Sens = 92.4% / Spec = 93.9% 
Experiment 2 (validate DSA with applicators after 4 months storage): 132 applicators read by 4 readers – Sens 91.7% / 
Spec  95.1% 
Experiment 3 (validate reproducibility of DSA): 132 applicators read by 5 readers: Sens = 87.6% / Spec = 95.2% 
Suggest further studies to validate DSA in after-sex applicators; 






Literature review: Vaginal Microbicide trials 
Authors, year Study  / design / Country / target 
population 
Findings Comments 




RCT, double-blind, placebo controlled, 
pericoital 1% TFV gel, South Africa, 
HIV uninfected women aged 18-40 
years, n=889 
Overall, 1% TFV gel reduced HIV acquisition by 39% BUT BY 
54% in women with high (>80%)  gel adherence 
38% in women with intermediate adherence (50-80%) 
28% in women with low adherence (<50%) 
Gel adherence defined as “estimated proportion of reported sex acts covered by 2 
doses of gel”; calculated: 1/2 the number of returned used apps each month / 
number of reported sex acts in that month 
Accurate estimate of product efficacy 
difficult in face of inadequate 
adherence.  
Future trials: greater emphasis on 
optimizing & objectively measuring 
adherence 




FACTS 001 (confirmatory  trial of 
CAPRISA 004) 
RCT, double-blind, placebo controlled, 
pericoital 1% TFV gel, South Africa, 
HIV uninfected women aged 18-30 
years, n=2059 
Overall, pericoital TFV gel not effective in preventing HIV acquisition 
In case-cohort sub study, high TFV in CVL associated with a 52% reduction in 
HIV acquisition (statistically significant) 
TFV gel effectiveness highest in women who reported use of product in >72% of 
sex acts (consistently as prescribed in all or most of sex acts), but this subgroup 
only represented about 20% of participants 
Association between adherence based 
on returned applicators and HIV 
effectiveness 
 
Conrad press release: FACTS 001 
Results presented at CROI 2015 
 
(6) 
As above As above High adherence in the overall study was 
too low to show TFV gel effectiveness  
Gel appeared acceptable and easy to 
use; most enrolled participants were 
young, unmarried, majority still living 
with parents and found consistent use 
of gel challenging 




RCT, placebo-controlled, daily oral 
TDF, daily oral TDF-FTC, or daily 1% 
TFV vaginal gel, Uganda, SA and 
Zimbabwe, HIV uninfected women 
aged 18-45 years, n=5029 
Study commenced Sept 2009; Sept 2011 DSMB recommends oral TDF arm be 
stopped due to futility; Nov 2011 DSMB recommends TFV gel arm be stopped due 
to futility; only TDF-FTC and oral placebo groups continued to study end in 
August 2012 
Mean adherence by returned-product counts =86%, by self-report in FTFI 90%, by 
ACASI 88%; however, subset analysis of 488 participants showed TFV detected in 
quarterly plasma samples in only 29% from TDF-FTC group, 30% in oral TDF 
group and 25% in TFV gel group 
For most women where TFV was not detected at first quarterly visit, none was 
detected at subsequent visits 
Detectable TFV levels at quarterly visit in TFV gel group had a significantly lower 
likelihood of HIV acquisition as compared to those with no TFV detected  
Predominantly young unmarried 
women in SSA with low adherence to 
daily oral or vaginal TFV based 
products, showed no protective effect. 
Single women under 25 least likely to 
adhere to study product and most likely 
to acquire HIV as compared to older 
married women 
Study highlighted “the need to better 
understand behavioural barriers in the 




Literature review: Adherence and Measurement in Microbicide trials 
Authors, year Brief summary of article and recommendations 





Descriptive of CAPRISA 004: Adherence interventions and rates  
Adherence measurement by 3 methods 
1. Returned used applicator (median # of applicators returned per study visit) 
2. Self-report (proportion of adherent sex acts over all sex acts for each woman) 
3. Applicator-based (primary measure) (half the number of returned used applicators / number of reported sex acts that month) 
Adherence calculated as 72.2% by applicator counts in relation to all reported sex acts cf. 82% self-reported during last sex act - suggesting a “white coat” effect: higher 
adherence in last sex act prior to scheduled study visit cf. to rest of the month. 
Returned used applicator counts are user-dependant, cannot account for frequency of sex, discarding gel, or forgetting to return applicators; self-report data in conjunction 
with objective applicator count gives a better applicator-based measure of adherence over 30 days prior to visit 





Descriptive of CAPRISA 008 which plans to assess implementation effectiveness and safety of coital TFV gel provision through existing Family Planning services, whilst 
providing post-trial access to TFV gel for those eligible women who participated in CAPRISA 004.  
Aims to address the question of future scale-up within SA public health system, should TFV gel reach licensure 
Adherence assessment via brief interviewer-administered instruments; counts of returned empty and unused applicators; genital specimens at quarterly and exit visits to be 
archived for analysis of markers of product adherence to aid interpretation of study results 
Results forthcoming 





Systematic review of oral PrEP & microbicide trials looking at adherence in terms of definitions and measures used, risk for non-adherence, adherence promotion 
strategies, effects on trial outcome: 19 trials published between 1987 – 2012 with 47 157 participants 
Self-report as an adherence measure upwardly biased in studies that employed multiple measures of adherence; adherence rate in microbicide studies ranged from 69-
89%; av. adherence higher when dosing was before every sex act as compared to once / twice daily application 
For oral PrEP: High adherers by pill count, self-report and refill data achieved 41% higher efficacy cf. with low adherers; in a microbicide trial reporting statistically 
significant treatment effect, high adherers by comparing gel returns and self-report of sexual frequency, had 26% higher efficacy 
Few risks for non-adherence reported, most often cited risk was decreased motivation over duration of study, sex with primary partner, running out of treatment 
Average of 3.3 adherence support strategies identified in each study reviewed 
Recommendations for future Bio-behavioural Prevention trials: 1) pre-trial assessment of potential barriers esp. in vulnerable populations, consider stigma towards use of 
B-BPSs, develop a risk-screen; 2) include evidence-based and culturally appropriate interventions to promote adherence, including option of partner involvement; 3) 
protocols must include plans to accurately monitor adherence during the trial, measure that lacks reporting bias should be included as one of several measures used for 
triangulation; improve validity and reliability of self-report by considering optimal recall time-frame, normalising nonadherence, assessment of fidelity (the extent to 
which interventions are implemented as intended by protocols); 4) development of B-BPS that does not adversely impact  pregnancy; 5) analysis of efficacy must include 
investigation of adherence as key effect moderator 





Evaluates methods of measuring adherence in recently completed microbicide trials, reviews strengths and limitations of methods, provides recommendations for future 
trial design 
Defines 4 dimensions of adherence (use as instructed):  initiation (first use), execution (how actual dosing corresponds to dosing regimen), discontinuation (product use is 
stopped), persistence (time between initiation and discontinuation) 
To understand effectiveness of product, need to measure timing and frequency in relation to infection risk, and sexual behaviours / practices that affect risk 
Discusses role of study population in assessing product efficacy: engaging partners could increase adherence  
Need to pay attention to trial communities in context of social and cultural issues; effect of site-specific cultural / economic factors on reporting of sensitive behaviours 
Bo-behavioural prevention: standardised measures to assess the dimensions of adherence and other behaviours needed for interpretation and comparison of results 
Need for respondent-independent measures; in interim use measures with complementary strengths; tools to measure adherence will depend on goal of researcher: to 
understand, quantify, influence, or all of these 





Reviews lessons learned from completed microbicide trials, with recommendations for future trials 
Describes 4 purposes of adherence data collection: determining effectiveness, adjuntive evidence to support results, understanding safety, monitoring acceptability and 
optimizing adherence  
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Authors, year Brief summary of article and recommendations 
Discusses practical experiences with adherence measures and strengths and weaknesses: direct measures (biomarkers of semen exposure, applicator tests, drug level 
assays and other biologic measures); indirect objective measures (applicator / pill counts); indirect self-reported measures; discusses strategies for improving 
measurement: mixed-method including triangulation, composite measures and baseline identification of predictors of adherence 
Describes approaches for optimizing adherence: at point of trial design; during study start; and during the trial as dictated by monitoring  
Recommendations: clarity regarding purpose of adherence data; consideration of adherence assessment in trial design and analysis; need to develop, test and validate new 
measurement approaches and improve indirect and self-report approaches; optimizing adherence in the trial setting (motivational, personal diaries, adherence buddies, 
individualised feedback on observed adherence patterns); cross-trial data collection and sharing; developing guidelines for reporting and analysing adherence 




Based on data and experience from completed microbicide efficacy trials, describes 6 adherence lessons learned: adherence measurement in clinical trials; understanding 
of instructions for use; unknown efficacy and effect on adherence; partner influence on product use; retention and continuation; generalisability of adherence behaviour. 
Provides recommendations for future work 




Describes the adherence support experiences from 4 PrEP trials: CAPRISA 004 (pericoital 1% TFV gel in women); FEM-PrEP ((daily oral TDF/TFC in women); iPrEX 
(daily oral TDF/FTC in MSM and Transgendered women); and VOICE (daily 1% TFV gel, oral TDF, and oral TDF/FTC in women) 
Estimated product use across the trials, sites and participants varied considerably, mostly lower than desired; most likely due to diversity of participant populations, 
culture and community; risk-perceptions; promoters and inhibitors of product use, and culture of sites 
Moving from biomedical to a bio-behavioural / bio-psycho-social framework will contribute to evidence for effective PrEP adherence interventions 
Agakos SW, Gable AR, Eds 
Methodological Challenges in 
Biomedical HIV Prevention Trials, 
Chapter 5. Design Considerations: 
Adherence 
National Academy of Sciences, 2008 
 
For trials showing overall benefit: interpretation of results should to be able to relate protective effect to adherence; 
For trials failing to show protective effect: need to distinguish whether non-effect is due to lack of product efficacy, lack of adherence, or increase in risky behaviour due 
to perception of protection; 
Understanding the predictors of non-adherence provides guidance into potential future HIV prevention interventions; 
Defining adherence by a single percentage may limit insights into adherence challenges, product acceptability, potential areas for intervention; 
Product adherence is complex – involves acceptance, execution and discontinuation of prescribed regimen; 
Compliance is persistence and quality of execution 





Undetected poor compliance in clinical trials may result in inability to show protective effect and an effective medicine being labelled as ineffective; 
Direct methods to measure / evaluate compliance: observation, biological markers, levels in biological fluids, spot checks 
Indirect measures: pill counts, electronic counters, pharmacy refills, questioning the patient during treatment, medication monitors, physiological markers, patient diaries, 
assessment through a school nurse 
Elaborates on reasons for poor compliance and methods to improve compliance 
Ideal method of measuring compliance not yet available, but use of multiple methods will yield reasonable data for most clinical trials 





Choice of adherence measurement method based on usefulness, reliability considering researchers goal, and resources available  
Adherence assessment in clinical trial pertinent to assess dose-response relationship and valid analysis of product efficacy  
Elaborates on direct & indirect methods for measuring adherence and compares methods; 
Ideal adherence monitoring method: inexpensive, reliable & objective, providing continuous record of compliance history, unobtrusive, easy to use and analyse 
Efficacy studies (phase IIa and IIb) require accurate measure of adherence 
Phase III studies: choice may depend on length, number of participants and sites – where feasible, combination of methods most effective  
Phase IV: consider longitudinal methods (electronic review of prescription records) combined with self-report 
Clinical practice: adapted self-report 




A review of DSA & other techniques to assess adherence; Discusses findings of various studies of methods of measuring adherence: 
Dye-Stain Assay of Microlax, HTI and Low-density Polyethylene applicators using Tryptan blue and FD&C Blue No. 1; Gram staining; Ultraviolet light assessment; 
DNA multiplex polymerase chain reaction tests; MEMS, using Wisebag; Drug levels 
Discusses concern regarding whether informing participants of adherence measurement using these techniques will influence their adherence: references research amongst 
sex workers in India where prior knowledge of assessment by DSA did not improve self-report nor encourage gel use; suggesting in some settings applicator tests may be 
incorporated without changing behaviour 
Reiterates applicator tests cannot verify expulsion of gel into vagina; who used the applicator; use in relation to sex; can calculate maximum number of applicators used, 
but cannot account for applicators lost, discarded or shared  




Literature review: Microbicides 
Authors, year Brief summary of article and recommendations 
Abdool Karim, Q et al, 2013 
 
(25) 
Discusses importance of Microbicides; history of efficacy trials; what’s new in microbicide development, next steps in product development, bio-behavioural challenges 
and multipurpose technologies; and gaps in microbicide research 
Women-initiated ARV-based prevention methods including microbicides important for young women, especially in Sub-Saharan Africa 
Better assessment and measurement of HIV exposure needed, better understanding of vaginal HIV acquisition needed 
Abdool Karim, S. et al, 2011 
 
(17) 
Proposed possible explanation for FEM-PrEP (daily oral TDF/FCT in women) trial results based on publicly available information and other PrEP studies: threshold 
concentrations for protection effect not yet been established; in CAPRISA 004, HIV incidence rate in women with TFV concentrations >1000 ng/mL was significantly 
lower as compared to placebo arm; tenofovir diphosphate concentrations are approximately 100-fold higher in rectal than vaginal tissues with TDF/FTC orally, and 
approximately 1000-fold higher in vaginal tissues with gel formulation than with TDF/FTC orally 
Effectiveness trials are crucial to provide information about effectiveness of TDF alone or in combination with FTC in preventing HIV in different populations, 
formulations, and routes of transmission; future clinical trials of tenofovir should aim for the highest tolerable drug concentration in vaginal tissues (until threshold 
required for protective effect is established); optimizing adherence in PrEP trials is critical; new PrEP formulations need to accurately assess required threshold 
concentrations of drug at site of HIV infection to confer protection 




Investigated the pharmacokinetic–pharmacodynamic relationship of 1% TFV gel in topical HIV prevention 
Assayed cervicovaginal fluid, plasma, and paired tissue samples from vagina and cervix of 34 women who seroconverted with random sample of 302 women who 
maintained HIV negative status in CAPRISA 004 



































APPENDIX G: UV Light Assessment log 
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APPENDIX K: Outcomes of assessment for inter-assessor agreement 
 
 










VIREA ASSESSOR 1 VIREA ASSESSOR 2 UVL ASSESSOR 1 UVL ASSESSOR 2
Appears unused Appears used Appears possibly used
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APPENDIX L: Supervisor-Student Memorandum of Understanding 
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